Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
about
Vaccines for preventing Japanese encephalitisThe Future of Smallpox Vaccination: is MVA the key?Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewThe evolution of poxvirus vaccinesJapanese encephalitis: the virus and vaccinesConstruction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.Production and characterization of vaccines based on flaviviruses defective in replicationNonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.A selectable and excisable marker system for the rapid creation of recombinant poxviruses.Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and catsJapanese encephalitis vaccines: moving away from the mouse brain.Recent advancement in flavivirus vaccine development.Vaccinia as a vector for gene delivery.A chimeric live attenuated vaccine against Japanese encephalitis.A Systematic Review of Recent Advances in Equine Influenza Vaccination.Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody responseConstruction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype І.Equine herpesvirus type 1 modified live virus vaccines: quo vaditis?Japanese encephalitis: development of new candidate vaccines.A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animalsCurrent use and development of vaccines for Japanese encephalitis.Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors.Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway.Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
P2860
Q24243819-B1DF869A-6489-4693-8E34-92077B01F3F8Q24801195-CB31E1E9-A441-4112-A6B3-F78C951C0808Q26700078-B154EE26-514B-4EB2-AEDD-E9C9E594E1ACQ26995905-002AB867-9A01-4133-8FD3-96F1CE467C89Q27010434-2E5A5BCC-0886-4F83-96D2-332E10CE3E50Q27469921-53737717-2858-445D-BBF0-43E030EEF590Q27486374-DB0D2893-9ACC-45CA-A8F9-7674983790F5Q30375489-22D88531-6A06-4C86-88E7-49D0D26383F0Q33602820-54EF4AA8-AE83-4D6A-9EDA-23F49F3391FEQ33743800-14D3EEE7-0257-4517-9F76-B9E1CF3BDE4FQ34023827-DED21117-D3D9-43BB-A2BB-4E9AE2633859Q35140435-F2AFC83A-8CCB-4249-8E75-97423802B149Q35194191-FC0C160C-E47D-44C4-9AAC-C9C367496F69Q35728621-FB2CEB92-45C2-48E4-9E72-65561134E30DQ35790868-239BC5E7-D275-4786-A40D-C217A4DF632AQ35791746-BEF2D365-08D8-4BC5-B0A3-A77D35796684Q35826722-F9030E98-BCBE-4510-83A0-E97495CB550FQ35834369-19B48443-4BE0-478F-AC99-7E1439F835ABQ35842621-75B1F5F9-73C3-4918-82A7-C2CA5D23CBF9Q35947683-7A24CB64-CD1F-4840-9338-E3A50B0B5CE9Q36190519-76415643-EBDF-4C26-A6D0-C93E1633DC1AQ36364196-F10C4F45-523F-45BE-9EA9-1317D0D8777AQ36383825-D1763EB1-B2E3-4D06-8326-44212B974062Q36441519-23DD33F4-B77C-4A16-8B00-FDB56E8D1711Q36559952-E9FC2978-B698-41E7-961E-82C80ECAADCDQ36844471-7A100900-73D5-43B9-8D41-071444A81FDAQ37032646-9B895DFD-F73D-4A33-9011-C014E994347DQ37113787-CAB58519-519A-480A-824E-8B47B4F7C133Q37309247-24207163-E5F8-4666-A2AC-F420760EA6B6Q39181962-A2F8D800-FA17-45ED-8F93-5AF5A1095DDBQ39220397-98924EAE-D294-46A2-A154-4CB05675434CQ40362454-568BFC23-093A-485B-AAE5-32A1DEAE4BB3Q42100401-F3EE5B7F-E88C-4907-AE64-90D7071CC4F4
P2860
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Safety and immunogenicity of N ...... ne and vaccinia-immune humans.
@en
Safety and immunogenicity of N ...... ne and vaccinia-immune humans.
@nl
type
label
Safety and immunogenicity of N ...... ne and vaccinia-immune humans.
@en
Safety and immunogenicity of N ...... ne and vaccinia-immune humans.
@nl
prefLabel
Safety and immunogenicity of N ...... ne and vaccinia-immune humans.
@en
Safety and immunogenicity of N ...... ne and vaccinia-immune humans.
@nl
P2093
P1433
P1476
Safety and immunogenicity of N ...... ne and vaccinia-immune humans.
@en
P2093
Kanesa-thasan N
P304
P356
10.1016/S0264-410X(00)00191-2
P407
P577
2000-10-01T00:00:00Z